Related Experiment Videos
Clinical studies with dopamine-receptor stimulants
Psychopharmacologia
|November 21, 1975
Summary
Oral ET-495 worsened psychiatric status in schizophrenic patients and induced psychosis in non-schizophrenics, suggesting dopamine
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Dopamine's role in schizophrenia is a long-standing hypothesis.
- Understanding dopamine receptor agonists' psychotogenic potential is crucial for developing effective treatments.
Observation:
- Oral administration of ET-495 led to psychiatric deterioration in schizophrenic patients.
- ET-495 induced paranoid states and auditory hallucinations in non-schizophrenic individuals.
Findings:
- The psychotogenic effects of oral ET-495 were less potent than those of amphetamine, methylphenidate, or L-Dopa.
- Intravenous ET-495 and apomorphine did not exhibit psychotogenic effects, contrasting with oral administration.
Implications:
- These findings support the involvement of dopamine in schizophrenic psychopathology.
- The difference in potency between oral and intravenous administration suggests complex pharmacokinetic or pharmacodynamic factors influencing ET-495's effects.
- Further research into receptor stimulators versus presynaptic agonists may clarify differing psychotogenic potencies.